Boehringer Ingelheim

Boehringer Ingelheim

CLSI validates Interpretive Criteria for the Susceptibility Testing of BI´s Ubrolexin® against Bovine Mastitis Pathogens

Ubrolexin®, a combination of kanamycin and cefalexin has been marketed for the intramammary treatment of clinical mastitis in lactating dairy cows in 27 countries by Boehringer-Ingelheim since 2008.  The combination broadens the spectrum of activity attributed to either agent alone, and synergy between the two agents has been demonstrated forRead more

Read More
Boehringer IngelheimPartner news

Blue sky thinking at first ever Global Milk Quality Expert Forum

The Global Milk Quality Expert Forum is a group of independent experts from academia and practice facilitated by Boehringer Ingelheim’s global udder health team. Its aim is to discuss and share thinkings and learings on new or important topics related to udder health. The intention is to run the meetingsRead more

Read More